This document discusses a case of pneumonia in an HIV-positive patient. The patient presents with fever, dyspnea, fatigue and other symptoms. A diagnosis of Pneumocystis jiroveci (formerly P. carinii) pneumonia is made, as this is a common opportunistic infection in HIV patients with low CD4 counts. The patient poses some infectious risk and should be isolated. The treatment plan involves 21 days of TMP-SMX antibiotics, with pentamidine or TMP-dapsone as alternatives. Hospitalization is required if the patient has respiratory failure or other severe symptoms.
2. Questions
Would you consider his chest condition to be potentially
infectious to others?
Should you isolate the patient in the mean time until his
condition proven to be non-infectious?
Outline treatment plan for the patient
3. Case
Positive Symptoms
Fever
Dyspnea
Fatigue
Qat use
Smoking
Unprotected sex
Chest pain
Pain and difficulty swallowing
Non-productive cough
Oral thrush
Weight loss
Sinus tachycardia
SaO2 91%
Negative Symptoms
No alcohol
No blood transfusions
No asthma
No illicit drug abuse
No respiratory tract infections
No urethral discharges
No diarrhea
No headache
No enlarged lymph nodes
Chest sound clear
No abnormal heart sounds
No skin abnormalities
5. Pneumocystis Jirovesi
Commonly found in lungs of
healthy people
Most common cause of
pneumonia in HIV patients
CD4 < 200
Classified as Fungal pneumonia
Does not respond to antifungal
treatment
6. Infectious or Not Infectious?
Opportunistic infection!
Standard precaution
Avoid placement in the
same room with an
immunocompromised
patient.
7. Treatment Plan
• TMP-SMX (trimethoprim-sulfamethoxazole): IV, 3 times a day
• 21 Days
• Pentamidine or TMP-dapsone: IV, 3 times a day
• 21 Days
• Corticosteroids
• In severe hypoxia
8. Treatment Plan
High rate of adverse
reactions with TMP-SMX
treatment
Adverse effects with
TMP-SMX are dose
related.
clinical visit with laboratory
evaluation one week after
discharge from the hospital.
patient with an adverse
reaction may still be able to
tolerate lower dose used for PJP
prophylaxis.
9. Treatment Plan
Intravenous therapy for PCP is required in any of
the following situations:
Respiratory status:
Wide A-a gradient
Poor oxygenation
Respiratory failure
When oral treatment cannot be
administered because of clinical status or
gastrointestinal issues
In patients who require Pentamidine (usually
because of multiple drug intolerances)
c
Suggested by:
above 45 mmHg
partial pressure of arterial oxygen < 60 mmHg
suggested by a high respiratory rate or a
PaCO2 that is normal or higher than
normal in a patient with hypoxia
10. Inpatient Vs. Outpatient
Indications for
hospitalization:
Disease severe enough
to warrant treatment with
corticosteroids
Initial treatment with
intravenous Pentamidine,
Patients for whom
compliance with therapy
or laboratory monitoring
is likely to be difficult
11. Summary
Most Common opportunistic infection in HIV patients is PJP
Treatment is initiated as early as possible
First Line therapy is TMP-SMX
Use corticosteroids in severe cases
Keep patient away from other immunocompromised patients
Editor's Notes
Patients with PCP may worsen clinically, with an increase in the alveolar-arterial oxygen gradient, two to three days after starting anti-Pneumocystis therapy, presumably because of increased inflammation in the lungs as organisms are killed. This worsening can often be prevented or blunted with corticosteroids that are administered at the initiation of therapy
1. regardless of whether intravenous or oral anti-Pneumocystis therapy is used
2. because of the potential side effects of therapy (in particular, hypoglycemia and hypotension)